FindTrial
Sign In

Application of artificial intelligence to guide individualized drug therapy in patients with heart failure after myocardial infarction

Application of artificial intelligence to guide individualized drug therapy in patients with heart failure after myocardial infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036802
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

Case series:Nil

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. All patients had heart failure after myocardial infarction, and signed informed consent of patients, and each patient had at least 6 months of follow-up information. (patients aged between 40 to 75 years, with a clear history of myocardial infarction, admitted to hospital for heart failure, with ejection fraction < 40% confirmed by echocardiography, excluding tumor and patients with life expectancy less than one year); 2. The patient has previously used any of ACEI (perindopril, enalapril, fosinopril) or ARB drugs (valsartan, losartan, telmisartan, irbesartan) or Arni (valsartan, losartan, telmisartan, irbesartan) or any of the beta blockers (metoprolol, bisoprolol, carvedilol) and spironolactone to form a three drug combination.

Exclusion criteria

Exclusion criteria: tumor and patients with life expectancy less than one year

Design outcomes

Primary

MeasureTime frame
Improvement of the symptoms and prognosis;—

Countries

China

Contacts

Public ContactHongli Li

Shanghai General Hospital

drhonglili@126.com+86 15316954067

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026